Launch Abbreviated: Teva Halts US Generic Sensipar Sales After Patent Deal With Amgen

Teva Pharmaceutical Industries Ltd.’s abbreviated US launch of the first Sensipar (cinacalcet) generic may have been just long enough to grab a small piece of Amgen Inc.’s lucrative market for the blockbuster calcium-sensing receptor agonist, but short enough not to trigger entry by other generic sponsors who previously settled patent litigation with Amgen.

The launch of Teva’s generic cinacalcet, which was quickly followed by a patent litigation settlement, also suggests that if Amgen settles with two other generic drug sponsors found not to have infringed Amgen’s formulation patent,